English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

The most common  EGFR  mutations in non‐small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to  EGFR ‐tyrosine kinase inhibitors. However, rare  EGFR  mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare  EGFR L747P  (2239‐2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. Herein, possible correlations between gene analysis and the outcomes of subsequent treatment are discussed.

thoracic cancer

Non‐small cell lung cancer harboring a rare  EGFR  L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report